BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 9111304)

  • 1. Function of the c-Myc antagonist Mad1 during a molecular switch from proliferation to differentiation.
    Cultraro CM; Bino T; Segal S
    Mol Cell Biol; 1997 May; 17(5):2353-9. PubMed ID: 9111304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the DNA-binding activities of Myc/Max/Mad network complexes during induced differentiation of U-937 monoblasts and F9 teratocarcinoma cells.
    Larsson LG; Bahram F; Burkhardt H; Lüscher B
    Oncogene; 1997 Aug; 15(6):737-48. PubMed ID: 9264414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Myc/Max/Mad network members in adipogenesis: inhibition of the proliferative burst and differentiation by ectopically expressed Mad1.
    Pulverer B; Sommer A; McArthur GA; Eisenman RN; Lüscher B
    J Cell Physiol; 2000 Jun; 183(3):399-410. PubMed ID: 10797315
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mmip-2, a novel RING finger protein that interacts with mad members of the Myc oncoprotein network.
    Yin XY; Gupta K; Han WP; Levitan ES; Prochownik EV
    Oncogene; 1999 Nov; 18(48):6621-34. PubMed ID: 10597267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mad1 expression in the absence of differentiation: effect of cAMP on the B-lymphoid cell line Reh.
    Naderi S; Blomhoff HK
    J Cell Physiol; 1999 Jan; 178(1):76-84. PubMed ID: 9886493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of E-box DNA binding during myeloid differentiation reveals complexes that contain Mad but not Max.
    Ryan KM; Birnie GD
    Biochem J; 1997 Jul; 325 ( Pt 1)(Pt 1):79-85. PubMed ID: 9224632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic in vivo interactions among Myc network members.
    Yin X; Landay MF; Han W; Levitan ES; Watkins SC; Levenson RM; Farkas DL; Prochownik EV
    Oncogene; 2001 Aug; 20(34):4650-64. PubMed ID: 11498788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Max transcription factor network: involvement of Mad in differentiation and an approach to identification of target genes.
    Hurlin PJ; Ayer DE; Grandori C; Eisenman RN
    Cold Spring Harb Symp Quant Biol; 1994; 59():109-16. PubMed ID: 7587059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined IFN-gamma and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells.
    Cetinkaya C; Hultquist A; Su Y; Wu S; Bahram F; Påhlman S; Guzhova I; Larsson LG
    Mol Cancer Ther; 2007 Oct; 6(10):2634-41. PubMed ID: 17938259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional regulation. Flipping the Myc switch.
    Bernards R
    Curr Biol; 1995 Aug; 5(8):859-61. PubMed ID: 7583141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis.
    Hurlin PJ; Foley KP; Ayer DE; Eisenman RN; Hanahan D; Arbeit JM
    Oncogene; 1995 Dec; 11(12):2487-501. PubMed ID: 8545105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mad proteins contain a dominant transcription repression domain.
    Ayer DE; Laherty CD; Lawrence QA; Armstrong AP; Eisenman RN
    Mol Cell Biol; 1996 Oct; 16(10):5772-81. PubMed ID: 8816491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation.
    Ayer DE; Eisenman RN
    Genes Dev; 1993 Nov; 7(11):2110-9. PubMed ID: 8224841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-induction of Mad1 and c-Myc in activated normal B lymphocytes.
    Ertesvåg A; Blomhoff HK; Beiske K; Naderi S
    Scand J Immunol; 2000 Jun; 51(6):565-70. PubMed ID: 10849366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zinc modulates c-Myc/Mad1 balance in human leukemia cells.
    Sirinian MI; Pisegna S; Paroli M; Militi S; Testa U; Peschle C
    Leukemia; 2003 Jan; 17(1):272-4. PubMed ID: 12529695
    [No Abstract]   [Full Text] [Related]  

  • 16. Mmip1: a novel leucine zipper protein that reverses the suppressive effects of Mad family members on c-myc.
    Gupta K; Anand G; Yin X; Grove L; Prochownik EV
    Oncogene; 1998 Mar; 16(9):1149-59. PubMed ID: 9528857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Switch from Myc/Max to Mad1/Max binding and decrease in histone acetylation at the telomerase reverse transcriptase promoter during differentiation of HL60 cells.
    Xu D; Popov N; Hou M; Wang Q; Björkholm M; Gruber A; Menkel AR; Henriksson M
    Proc Natl Acad Sci U S A; 2001 Mar; 98(7):3826-31. PubMed ID: 11274400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MAD1 and its life as a MYC antagonist: an update.
    Lüscher B
    Eur J Cell Biol; 2012; 91(6-7):506-14. PubMed ID: 21917351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3.
    Ayer DE; Lawrence QA; Eisenman RN
    Cell; 1995 Mar; 80(5):767-76. PubMed ID: 7889570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repression of Myc-Ras cotransformation by Mad is mediated by multiple protein-protein interactions.
    Koskinen PJ; Ayer DE; Eisenman RN
    Cell Growth Differ; 1995 Jun; 6(6):623-9. PubMed ID: 7669717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.